{"id":1289,"date":"2019-08-14T19:47:25","date_gmt":"2019-08-14T11:47:25","guid":{"rendered":"http:\/\/www.bioactivescreeninglibrary.com\/?p=1289"},"modified":"2022-01-07T10:54:16","modified_gmt":"2022-01-07T02:54:16","slug":"tsa-compromising-superior-safety-oncolytic-virus-evidenced","status":"publish","type":"post","link":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/2019\/08\/14\/tsa-compromising-superior-safety-oncolytic-virus-evidenced\/","title":{"rendered":"With TSA without compromising the superior safety of this oncolytic virus as evidenced"},"content":{"rendered":"

From viral bio-distribution studies done for this virus in control conditions or in presence of TSA. We further tested the possibility that the combination of B18R-deleted vaccinia virus and TSA could be effective in a human xenograft tumour model. Immunocompromised mice with palpable HCT-116 colon cancer tumours were treated with TSA and a luciferase-expressing B18R\/TK-deleted virus and IVIS imaging was used to examine the growth of the virus in tumour bearing mice. Treatment with TSA resulted in Z-VAD-FMK<\/a> increased virus-associated luciferase activity within HCT-116 tumours when compared to treatment with vaccinia virus alone. The low virus signal in the lungs after 48 h is consistent with the biodistribution data; however this signal is gone by 4 days. Importantly the signal in the lungs is not enhanced by TSA treatment whereas the signal is greatly enhanced in the tumour. Consistent with this observation and the results obtained in the lung metastasis model, mice treated with the combination of TSA and TK\/ B18R-deleted WR had delayed tumor progression and demonstrated increased survival versus mice treated with either agent alone. Trichostatin A was one of the first HDAC inhibitors to be discovered and although its anti-cancer properties are well documented, its sub-optimal in vivo stability has made it less attractive for use as a chronically administered anti-cancer drug. A considerable effort in the HDI field has led to the development of more stable TSA derivatives such as Vorinistat H, which was recently approved for limited applications like treatment of CTCL. In this study we found that SAHA was significantly less effective at augmenting vaccinia virus spread in vitro than TSA. In this context, we also found that TSA interacted synergistically with vaccinia virus, leading to better cell killing. Theoretically, this synergistic interaction predicts that the effective dose used for each therapeutic in vivo could be reduced while retaining efficient anti-tumour activity. However, since OVs need to overcome numerous physiological barriers in order to reach tumors, it is likely that TSA\/Vaccinia combination therapy would be best used as a means to increase efficacy as opposed to dose reduction. Nonetheless, this suggests that the relatively short half-life of TSA in vivo may not be a concern for the therapeutic application described here in light of the relative potency of its vaccinia-enhancing effect. Oncolytic virus therapy is an acute treatment with curative intent. Indeed the activity of OVs involves not only SAR131675 1433953-83-3<\/a> replication in, and destruction of tumour cells but also the recruitment of host immune cells to the tumour bed leading to the initiation of antitumour immunity. It is known that HDIs can impact the patient\ufffd\ufffds immune cells and thus a fast acting, virus enhancing, compound that is rapidly cleared once an infection is established may be preferred. Furthermore the short half-life of TSA allows for better control over the OV dose should treatment need to be stopped abruptly. Given that our data shows anti-tumoral activity of several different VV strains can be enhanced by TSA in vivo the clinical application of TSA may need to be re-visited. This is of considerable interest since VV strains such as JX-594 and JX-929 are currently undergoing Phase I\/II clinical trials. The effect of TSA on the IFN response is well documented and the enhancing effect of HDIs such as TSA on IFNsensitive strains including VSV and HSV has been previously reported. It is therefore not surprising that TSA can increase the activity of B18R-deleted VV strains.<\/p>\n","protected":false},"excerpt":{"rendered":"

From viral bio-distribution studies done for this virus in control conditions or in presence of TSA. We further tested the possibility that the combination of B18R-deleted vaccinia virus and TSA could be effective in a human xenograft tumour model. Immunocompromised mice with palpable HCT-116 colon cancer tumours were treated with TSA and a luciferase-expressing B18R\/TK-deleted … Continue reading “With TSA without compromising the superior safety of this oncolytic virus as evidenced”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1289"}],"collection":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=1289"}],"version-history":[{"count":1,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1289\/revisions"}],"predecessor-version":[{"id":1290,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1289\/revisions\/1290"}],"wp:attachment":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=1289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=1289"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=1289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}